HELP PROTECT WHAT MATTERS: DESIGN AND PERFORMANCE OF ALINITY M TRANSPLANT ASSAYS (CMV AND EBV)

Cytomegalovirus (CMV) and Epstein Barr Virus (EBV) are found in high global seroprevalence. Infections usually are asymptomatic or manifest as mild or subclinical disease in immunocompetent individuals and establish life-long latency without causing serious health problems. However, in immunocompromised patients such as transplant recipients, reactivation of latent virus can result in severe disease. Patient monitoring, including quantitative nucleic acid testing (QNAT), may play an important role in patient management. Alinity m CMV and Alinity m EBV assays are quantitative in vitro polymerase chain reaction assays with a dual-target design to aid in redundancy in detection. This webinar will discuss the design and performance of the Alinity m CMV and Alinity m EBV assays.

 

Learning Objectives

 

 

Alinity m CMV and Alinity m EBV assays are CE-marked.  Check with your local representative for availability in specific markets.